Results 271 to 280 of about 18,452 (302)

Role of endothelin and endothelin receptor antagonists in renal disease

European Journal of Clinical Investigation, 2006
AbstractEndothelin (ET)‐1 is a potent vasoconstrictor peptide with pro‐inflammatory, mitogenic, and pro‐fibrotic properties that is closely involved in both normal renal physiology and pathology. ET‐1 exerts a wide variety of biological effects, including constriction of cortical and medullary vessels, mesangial cell contraction, stimulation of ...
W. Neuhofer, D. Pittrow
openaire   +3 more sources

Endothelin Receptor Antagonists in Cancer Therapy

Cancer Investigation, 2007
Endothelins are a family of peptide compounds which exert regulatory control over cellular processes important for growth, survival, invasion, and angiogenesis. In particular, endothelin-1, acting primarily through the endothelin-A receptor, is implicated in the neoplastic growth of multiple tumor types.
George Wilding, Mihailo Lalich, Glenn Liu, Douglas G. McNeel   +3 more
openaire   +3 more sources

Update on Endothelin Receptor Antagonists in Hypertension

Current Hypertension Reports, 2018
To review the most recent data on the development of endothelin receptor antagonists (ERAs) for the treatment of hypertension and the management of diabetic nephropathy RECENT FINDINGS: Recent reviews and meta-analyses of experimental and clinical data obtained with ERAs confirmed that endothelin receptor blockade is associated with significant ...
openaire   +3 more sources

Endothelin receptor antagonists – their role in pulmonary medicine

Revue des Maladies Respiratoires, 2011
Understanding of the function of endothelin-1 in the pathophysiology of endothelial disease, in particular pulmonary arterial hypertension (PAH), has paved the way for the development of endothelin-receptor antagonists (ERAs) and explains the leading role they now play in the treatment armamentarium for this disease.Three active ERA drugs (bosentan ...
M. Reynaud-Gaubert, S. Boniface
openaire   +3 more sources

The Antagonists of Endothelin Receptors: Results and Perspectives

Current Pharmaceutical Analysis, 2005
In 1988 Yanagisawa described endothelins, a new class of vasoconstrictor agents produced by endothelial cells. Further biological effects of these peptides have subsequently been demonstrated, for example, induction of cell proliferation and fibrosis.
openaire   +3 more sources

Endothelin receptor antagonists for pulmonary arterial hypertension

2003
Pulmonary arterial hypertension (PAH) is a devastating disease, which leads to right heart failure and premature death. Pulmonary arterial hypertension can be classified into five categories according to Venice classification: (1) Idiopathic PAH; (2) Familial PAH; (3) PAH associated with collagen vascular disease, congenital systemic-to-pulmonary ...
C, Liu, J, Cheng
openaire   +3 more sources

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Ca-A Cancer Journal for Clinicians, 2023
Laura A Huppert, Hope S Rugo
exaly  

Critical care management of chimeric antigen receptor T‐cell therapy recipients

Ca-A Cancer Journal for Clinicians, 2022
Alexander Shimabukuro-vornhagen, Victoria Metaxa, Elie Azoulay   +2 more
exaly  

Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice

Ca-A Cancer Journal for Clinicians, 2023
Rujul H Parikh
exaly  

Endothelin receptor antagonists‐induced hepatotoxicity

Internal Medicine Journal, 2013
C. de la Fuente Honrubia, Ferrán Catalá-López, D. Macías Saint-Gerons, Dolores Montero   +3 more
openaire   +3 more sources